CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity
11 nov. 2024 08h15 HE
|
CERo Therapeutics Holdings, Inc.
Data presented as part of a poster at the SITC 2024 Conference SOUTH SAN FRANCISCO, Calif., Nov. 11, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo”), an...
Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
23 sept. 2024 08h55 HE
|
Kronos Bio, Inc.
– New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance – – New PK/PD results demonstrate that istisociclib...
Kronos Bio Announces Participation in Medical and Investor Conferences in September
03 sept. 2024 08h55 HE
|
Kronos Bio, Inc.
SAN MATEO, Calif., and CAMBRIDGE, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to developing small molecule therapeutics that address cancers and...
New to The Street Announces the Televised Lineups for Shows 471, 472, and 473; Airings on Three Networks Will Begin on Saturday, May 27, 2023, at 3:30 PM ET
26 mai 2023 09h15 HE
|
FMW Media Works Corp
NEW YORK, May 26, 2023 (GLOBE NEWSWIRE) -- FMW Media's New to The Street, a premier business television show, announces its corporate interviews on three episodes, 471, 472, and 473, airing as a...
Stingthera, Inc. Announces Clinical Collaboration with Merck to Evaluate SNX281 in Combination With KEYTRUDA® (pembrolizumab) in Certain Patients with Advanced Solid Tumors and Lymphoma
03 nov. 2021 06h45 HE
|
Stingthera, Inc.
BOSTON, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Stingthera, Inc. today announced it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the United States and Canada)...
Atossa Therapeutics Announces Ovarian Cancer Patient has Begun Treatment with Oral Endoxifen under FDA’s Expanded Access Pathway
08 avr. 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, April 08, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
Atossa Therapeutics Announces Receipt of FDA Safe to Proceed Letter for Treatment of an Ovarian Cancer Patient with Oral Endoxifen Under Expanded Access Pathway
11 mars 2021 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 11, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of...
PUREOLOGY CONTINUES IN THE FIGHT AGAINST OVARIAN CANCER WITH THE NATIONAL OVARIAN CANCER COALITION
14 mai 2018 12h41 HE
|
National Ovarian Cancer Coalition
DALLAS, TX, May 14, 2018 (GLOBE NEWSWIRE) -- Pureology has committed to continue its support of the National Ovarian Cancer Coalition’s efforts in the fight against ovarian cancer. The...